EANS-Adhoc: Marseille-Kliniken AG: Uwe Bergheim and Prof. Matthias Schönermark announce their resignation from the supervisory board
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Resignation of members of the supervisory board 19.10.2012 Hamburg, 19 October 2012 - Following an extraordinary general meeting today, Messrs Uwe Bergheim and Prof. Dr. med. Matthias P. Schönermark have announced their intention to resign from the supervisory board of Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with the end of the annual general meeting which is planned for 3 December 2012. end of ad-hoc-announcement ================================================================================ About Marseille-Kliniken AG: Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57 residential care facilities, three residential units for assisted living and about 4,700 employees is a market leading listed company on health care in Germany. The business model is significantly influenced by the demographic development. Therefore Marseille-Kliniken AG has a secured future. Short-term economic fluctuations on the other hand exert only a minor influence. As a consistently modern company with strong focus on quality, the private enterprise is in a good position within a competitive environment primarily characterized by regionally active charities. Further inquiry note: Hillermann Consulting Jan Pahl Investor Relations for Marseille-Kliniken AG Poststraße 14-16 20354 Hamburg Germany Tel.: +49 - (0)40 / 3202791-0 www.marseille-kliniken.de end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: Marseille-Kliniken AG Alte Jakobstraße 79/80 D-10179 Berlin phone: +49 (0)30 246 32-400 FAX: +49 (0)30 246 32-401 mail: info@marseille-kliniken.de WWW: http://www.marseille-kliniken.de sector: Pharmaceuticals ISIN: DE0007783003 indexes: CDAX, Classic All Share, Prime All Share stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing: Hamburg, regulated dealing/prime standard: Frankfurt language: English
Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell